We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® (CT03Ext)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01111383
Recruitment Status : Completed
First Posted : April 27, 2010
Last Update Posted : November 21, 2011
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.

April 13, 2010
April 27, 2010
November 21, 2011
September 2009
May 2011   (Final data collection date for primary outcome measure)
to assess safety profile in terms of incidence of adverse events/adverse drug reactions, frequency of cystic fibrosis exacerbations, audiometric test, laboratory parameters (hematology and blood chemistry), vitals signs (hr and bp), physical examination. [ Time Frame: up to 48 weeks ]
Same as current
Complete list of historical versions of study NCT01111383 on ClinicalTrials.gov Archive Site
  • to assess whether prolonged use of aerosolized tobramycin is required to sustain FEV1 increase (FEV1 expressed in liters and % predicted) [ Time Frame: up to 48 weeks ]
  • Categorical results of microbiological tests referred to P. aeruginosa (negativisation, persistence, superinfection, re-infection); susceptibility testing of isolated P. aeruginosa strains (MIC90 and MIC50) [ Time Frame: up to 48 weeks ]
  • Changes in body weight and BMI [ Time Frame: up to 48 weeks ]
  • to assess health related quality of life [ Time Frame: Initial visit, Week 20, Week 44 ]
Same as current
Not Provided
Not Provided
A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
A Single Arm 48-Week Follow-on Safety Study to the Core Study (A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa)
This is a 48-week extension study to CMA-0631-PR-0010 Core Study. Patients who have a positive culture for P. aeruginosa at visit 4 of the first 8-week core study period and/or if deemed appropriate by the Investigators will be able to be included in the 48-week follow-on period (Extension Study) to continue the treatment only with Bramitob® (tobramycin nebuliser solution, 300 mg twice daily in 4 mL unit dose vials).
Not Provided
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Cystic Fibrosis
Drug: tobramycin
300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 "on" cycles of 4 weeks duration during the 48-week period.
Other Name: Tobrineb®/Actitob®/Bramitob®
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
May 2011
May 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Successful completion of Core Study
  • At least 6 years of age
  • Males and females
Sexes Eligible for Study: All
6 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
France,   Poland,   Ukraine
CMA-0631-PR-0010 Extension
Not Provided
Not Provided
Chiesi Farmaceutici S.p.A.
Chiesi Farmaceutici S.p.A.
Not Provided
Principal Investigator: Henryk Mazurek, Doctor Klinika Pneumonologii i Mukowiscydozy, Instytut Gruzlicy i Chorob Pluc w Rabce Zdroj
Chiesi Farmaceutici S.p.A.
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP